Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
Annamaria Brioli1, Paola Tacchetti, Elena Zamagni
1"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
Expert Review of Anticancer Therapy
|March 4, 2014
Summary
Novel agents improve multiple myeloma (MM) outcomes. This review explores maintenance therapy strategies, including continuous treatment with new drugs, to achieve deeper responses and sustained remission in MM patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Novel agents have significantly improved outcomes for patients with Multiple Myeloma (MM).
- Achieving deep complete response and sustained remission are crucial for potential cure.
- Consolidation and maintenance therapies are integral to modern MM treatment paradigms.
Purpose of the Study:
- To review current and investigational maintenance therapy strategies for Multiple Myeloma.
- To discuss the role of novel agents in continuous treatment for MM.
- To address the lack of consensus on maintenance therapy and consider new biological insights.
Main Methods:
- Literature review of novel agents and maintenance strategies in Multiple Myeloma.
- Analysis of clinical trial data and expert opinions on MM therapy.
- Discussion of emerging biological concepts, such as intra-clonal heterogeneity.
Main Results:
- Novel agents demonstrate excellent activity, supporting their investigation in maintenance therapy.
- Promising results exist for continuous treatment with novel agents in MM.
- A definitive consensus on optimal maintenance therapy strategies is still lacking.
Conclusions:
- Maintenance therapy is a key component in achieving deep and sustained responses in MM.
- Novel agents show significant promise for MM maintenance, but further research and consensus are needed.
- Understanding intra-clonal heterogeneity may inform future personalized maintenance strategies in MM.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
12.5K
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.2K
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:22Myocarditis IV: Nursing Management
398
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
398
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
01:16Therapeutic Drug Monitoring: Overview and Classification
642
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
642